Clinical Trials
251 trialsNeoB-Cap1
Novartis
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
OMNIRAY
Eli Lilly and Company
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
OP-NEU-101
Onchilles Pharma Inc
TB06
AstraZeneca
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca
PROBE-CTC
ScreenCell
SERENA-6
AstraZeneca
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ASPEN-09-03
ALX Oncology Inc.
SELECT-2CAR
Beijing Biotech
BRIA-ABC
BriaCell Therapeutics Corporation
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Beijing Biotech
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
INX-315-01
Incyclix Bio
DUAL-NK-BC
Beijing Biotech
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
KEYNOTE-B49
Merck Sharp & Dohme LLC
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
PROVIDENCE
AstraZeneca
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
IntoCell, Inc
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
OlympiAD
AstraZeneca
GUARDIAN-101
Clasp Therapeutics, Inc.
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
VIKTORIA-1
Celcuity Inc
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
SHARON
General Oncology, Inc.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd